...
机译:减少临床高风险,基因组低风险PN0和PN1早期乳腺癌患者的化疗:来自前瞻性的五年数据,随机三期3西德语学习组(WSG)Planb审判
West German Study Grp Ludwig Weber Str 15 D-41061 Monchengladbach Germany;
West German Study Grp Ludwig Weber Str 15 D-41061 Monchengladbach Germany;
Med Sch Hannover Inst Pathol Carl Neuberg Str 1 D-30625 Hannover Germany;
West German Study Grp Ludwig Weber Str 15 D-41061 Monchengladbach Germany;
Clin Mutterhaus Borromaerinnen Dept Oncol Feldstr 16 D-54290 Trier Germany;
Univ Clin Cologne Dept Gynecol &
Obstet Breast Ctr Kerpener Str 62 D-50937 Cologne Germany;
Evangel Hosp Dept Gynecol &
Obstet Ferrenbergstr 24 D-51465 Bergisch Gladbach Germany;
Univ Clin Essen Dept Gynecol &
Obstet Hufelandstr 55 D-45147 Essen Germany;
Clin Essen Mitte Breast Ctr Henricistr 92 D-45136 Essen Germany;
Clin Suedstadt Dept Gynecol &
Obstet Sudring 81 D-18059 Rostock Germany;
Johanniter Clin Stendal Breast Ctr Altmark Bahnhofstr 24-26 D-39576 Stendal Germany;
Dr Horst Schmidt Clin Dept Gynecol Ludwig Erhard Str 100 D-65199 Wiesbaden Germany;
Klinikum Chemnitz Flemmingstr 2 D-09116 Chemnitz Germany;
Teutoburger Str 60 D-33604 Bielefeld Germany;
Breast Ctr Ostbayern Perlasberger Str 41 D-94469 Deggendorf Germany;
West German Study Grp Ludwig Weber Str 15 D-41061 Monchengladbach Germany;
Genom Hlth Inc Redwood City CA USA;
Genom Hlth Inc Redwood City CA USA;
West German Study Grp Ludwig Weber Str 15 D-41061 Monchengladbach Germany;
Med Sch Hannover Inst Pathol Carl Neuberg Str 1 D-30625 Hannover Germany;
West German Study Grp Ludwig Weber Str 15 D-41061 Monchengladbach Germany;
Genomic signature; Oncotype DX; Breast cancer; Ki-67; IHC4;
机译:减少化疗在临床高风险,基因组低风险的PN0和PN1早期乳腺癌患者中:从前瞻性,随机第3阶段3西德语学习组(WSG)Planb审判的五年数据(Vol 165,PG 573,2017)
机译:前瞻性期III WSG Planb试验的五年结果确认在高风险HR + / HER2-早期乳腺癌(EBC)患者中的21-基因复发评分对1-3名涉及的淋巴结患者的预后影响
机译:WSG III期PlanB的前瞻性试验:随访5年的临床结果以及21个基因复发评分结果的影响,HR // HER2高危淋巴结阴性和阳性的等级,ER,PR和Ki67的中央/局部病理学检查乳腺癌
机译:使用微阵列和临床数据鉴定高危乳腺癌患者
机译:通过比较不同统计方法对晚期乳腺癌患者的临床试验的生活质量数据进行分析。
机译:减少临床上高风险基因组低风险的pN0和pN1早期乳腺癌患者的化疗使用:前瞻性随机3期西德研究小组(WSG)PlanB试验的五年数据
机译:TILs与临床参数,复发得分®结果,早期HER2阴性乳腺癌患者的预后(BC)-A转型分析,对未来的WSG PLANB试验